Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between
Temozolomide cycles in treating patients with glioblastoma that has come back or does not
respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a
subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear
cells, can specifically attack patient glioblastoma cells that expressing B7-H3.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University